FUNCTIONAL ANALYSIS OF NF2 GENE MUTATIONS

NF2基因突变的功能分析

基本信息

  • 批准号:
    6193800
  • 负责人:
  • 金额:
    $ 33.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-07-28 至 2004-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (From the applicant's abstract): Little is known about the molecular pathogenesis of nervous system tumors such as meningiomas and schwannomas. Individuals affected with neurofibromatosis 2 (NF2) develop these tumors at increased frequency. In addition, mutations and loss of NF2 gene expression are associated with the development of sporadic schwannomas and meningiomas, suggesting that the NF2 gene product, merlin is a critical growth regulator for Schwann cells and meningeal cells. The NF2 tumor suppressor gene bears sequence similarity to Protein4.1 proteins that link the actin cytoskeleton to cell surface glycoproteins. Previous work from out laboratory has demonstrated that merlin regulates cell motility and proliferation as well as cell spreading. In this application we propose to test the hypothesis that merlin integrates several different several cellular processes important for tumor formation and progression reflected by its ability to regulate cell spreading (tumor initiation), cell proliferation (tumor growth) and cell motility (tumor spread). The experiments proposed in this application are aimed at determining how the merlin tumor suppressor functions as a negative growth regulator by defining merlin functional domains, critical merlin protein interactions and relevant intracellular signaling pathways. Our ability to design rational therapies for schwannomas and meningiomas is dependent on an improved understanding of the mechanisms by which loss of merlin expression and function promotes tumor formation.
描述(摘自申请人摘要):我们对……知之甚少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David H Gutmann其他文献

Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
儿科低级别胶质瘤:最先进的技术和持续的挑战。
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    15.9
  • 作者:
    J. Fangusaro;D. Jones;R. Packer;David H Gutmann;T. Milde;O. Witt;Sabine Mueller;Michael J Fisher;J. Hansford;U. Tabori;Darren R Hargrave;P. Bandopadhayay
  • 通讯作者:
    P. Bandopadhayay

David H Gutmann的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David H Gutmann', 18)}}的其他基金

Neuronal Regulation of Low-Grade Gliomagenesis
低度胶质瘤发生的神经元调节
  • 批准号:
    10412883
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
Neuronal Regulation of Low-Grade Gliomagenesis
低度胶质瘤发生的神经元调节
  • 批准号:
    10596172
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
T Cell Regulation of Low-Grade Glioma
低级别胶质瘤的 T 细胞调节
  • 批准号:
    10700099
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity
定义神经纤维瘤病-1神经系统疾病异质性的机制基础
  • 批准号:
    10533079
  • 财政年份:
    2016
  • 资助金额:
    $ 33.4万
  • 项目类别:
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity
定义神经纤维瘤病-1神经系统疾病异质性的机制基础
  • 批准号:
    10534120
  • 财政年份:
    2016
  • 资助金额:
    $ 33.4万
  • 项目类别:
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity
定义神经纤维瘤病-1神经系统疾病异质性的机制基础
  • 批准号:
    10062526
  • 财政年份:
    2016
  • 资助金额:
    $ 33.4万
  • 项目类别:
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
定义 NF1 视神经胶质瘤的危险因素
  • 批准号:
    9171983
  • 财政年份:
    2016
  • 资助金额:
    $ 33.4万
  • 项目类别:
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
定义 NF1 视神经胶质瘤的危险因素
  • 批准号:
    9333268
  • 财政年份:
    2016
  • 资助金额:
    $ 33.4万
  • 项目类别:
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity
定义 Neurophimatosis-1 神经系统疾病异质性的机制基础
  • 批准号:
    10302300
  • 财政年份:
    2016
  • 资助金额:
    $ 33.4万
  • 项目类别:
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
定义 NF1 视神经胶质瘤的危险因素
  • 批准号:
    9751813
  • 财政年份:
    2016
  • 资助金额:
    $ 33.4万
  • 项目类别:

相似海外基金

Energizing and Protecting Axons Through Metabolic Coupling to Schwann Cells
通过与雪旺细胞的代谢耦合来激活和保护轴突
  • 批准号:
    10647707
  • 财政年份:
    2023
  • 资助金额:
    $ 33.4万
  • 项目类别:
Energizing and Protecting Axons Through Metabolic Coupling to Schwann Cells
通过与雪旺细胞的代谢耦合来激活和保护轴突
  • 批准号:
    10768040
  • 财政年份:
    2023
  • 资助金额:
    $ 33.4万
  • 项目类别:
The role of change in expression levels of coagulation factors in Schwann cells in the neuropathic pain
雪旺细胞凝血因子表达水平变化在神经病理性疼痛中的作用
  • 批准号:
    23K06372
  • 财政年份:
    2023
  • 资助金额:
    $ 33.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Role of Schwann Cells in the Progression of Melanoma
雪旺细胞在黑色素瘤进展中的作用
  • 批准号:
    10574973
  • 财政年份:
    2023
  • 资助金额:
    $ 33.4万
  • 项目类别:
YAP/TAZ in Schwann Cells as Potential Therapeutic Targets in CMT1A and HNPP.
雪旺细胞中的 YAP/TAZ 作为 CMT1A 和 HNPP 的潜在治疗靶点。
  • 批准号:
    10730544
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
Influence of peripheral schwann cells on neuropathic pain
外周雪旺细胞对神经病理性疼痛的影响
  • 批准号:
    22K09026
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Metabolic coupling between Schwann cells and axons is functionally distinct from myelination and is disrupted in obesity, prediabetes, and diabetes
雪旺细胞和轴突之间的代谢耦合在功能上不同于髓鞘形成,并且在肥胖、糖尿病前期和糖尿病中被破坏
  • 批准号:
    10689253
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
YAP/TAZ in Schwann Cells as potential therapeutic targets in CMT1A and HNPP.
雪旺细胞中的 YAP/TAZ 作为 CMT1A 和 HNPP 的潜在治疗靶点。
  • 批准号:
    10537511
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
Creating new therapies for lung cancer by targeting de-differentiated Schwann cells in the cancer microenvironment.
通过靶向癌症微环境中的去分化施万细胞,创造肺癌新疗法。
  • 批准号:
    22K09004
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Metabolic coupling between Schwann cells and axons is functionally distinct from myelination and is disrupted in obesity, prediabetes, and diabetes
雪旺细胞和轴突之间的代谢耦合在功能上不同于髓鞘形成,并且在肥胖、糖尿病前期和糖尿病中被破坏
  • 批准号:
    10518251
  • 财政年份:
    2022
  • 资助金额:
    $ 33.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了